Decline in Left Ventricular Ejection Fraction During Follow-Up in Patients With Severe Aortic Stenosis.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
23 12 2019
Historique:
received: 21 05 2019
revised: 15 08 2019
accepted: 05 09 2019
entrez: 21 12 2019
pubmed: 21 12 2019
medline: 21 7 2020
Statut: ppublish

Résumé

The aim of this study was to investigate the prognostic impact of the decline in left ventricular ejection fraction (LVEF) at 1-year follow-up in patients with severe aortic stenosis (AS) managed conservatively. No previous study has explored the association between LVEF decline during follow-up and clinical outcomes in patients with severe AS. Among 3,815 patients with severe AS enrolled in the multicenter CURRENT AS (Contemporary Outcomes After Surgery and Medical Treatment in Patients With Severe Aortic Stenosis) registry in Japan, 839 conservatively managed patients who underwent echocardiography at 1-year follow-up were analyzed. The primary outcome measure was a composite of AS-related deaths and hospitalization for heart failure. There were 91 patients (10.8%) with >10% declines in LVEF and 748 patients (89.2%) without declines. Left ventricular dimensions and the prevalence of valve regurgitation and atrial fibrillation or flutter significantly increased in the group with declines in LVEF. The cumulative 3-year incidence of the primary outcome measure was significantly higher in the group with declines in LVEF than in the group with no decline (39.5% vs. 26.5%; p < 0.001). After adjusting for confounders, the excess risk of decline in LVEF over no decline for the primary outcome measure remained significant (hazard ratio: 1.98; 95% confidence interval: 1.29 to 3.06). When stratified by LVEF at index echocardiography (≥70%, 60% to 69%, and <60%), the risk of decline in LVEF on the primary outcome was consistently seen in all the subgroups, without any interaction (p = 0.77). Patients with severe AS with >10% declines in LVEF at 1 year after diagnosis had worse AS-related clinical outcomes than those without declines in LVEF under conservative management. (Contemporary Outcomes After Surgery and Medical Treatment in Patients With Severe Aortic Stenosis Registry; UMIN000012140).

Sections du résumé

OBJECTIVES
The aim of this study was to investigate the prognostic impact of the decline in left ventricular ejection fraction (LVEF) at 1-year follow-up in patients with severe aortic stenosis (AS) managed conservatively.
BACKGROUND
No previous study has explored the association between LVEF decline during follow-up and clinical outcomes in patients with severe AS.
METHODS
Among 3,815 patients with severe AS enrolled in the multicenter CURRENT AS (Contemporary Outcomes After Surgery and Medical Treatment in Patients With Severe Aortic Stenosis) registry in Japan, 839 conservatively managed patients who underwent echocardiography at 1-year follow-up were analyzed. The primary outcome measure was a composite of AS-related deaths and hospitalization for heart failure.
RESULTS
There were 91 patients (10.8%) with >10% declines in LVEF and 748 patients (89.2%) without declines. Left ventricular dimensions and the prevalence of valve regurgitation and atrial fibrillation or flutter significantly increased in the group with declines in LVEF. The cumulative 3-year incidence of the primary outcome measure was significantly higher in the group with declines in LVEF than in the group with no decline (39.5% vs. 26.5%; p < 0.001). After adjusting for confounders, the excess risk of decline in LVEF over no decline for the primary outcome measure remained significant (hazard ratio: 1.98; 95% confidence interval: 1.29 to 3.06). When stratified by LVEF at index echocardiography (≥70%, 60% to 69%, and <60%), the risk of decline in LVEF on the primary outcome was consistently seen in all the subgroups, without any interaction (p = 0.77).
CONCLUSIONS
Patients with severe AS with >10% declines in LVEF at 1 year after diagnosis had worse AS-related clinical outcomes than those without declines in LVEF under conservative management. (Contemporary Outcomes After Surgery and Medical Treatment in Patients With Severe Aortic Stenosis Registry; UMIN000012140).

Identifiants

pubmed: 31857020
pii: S1936-8798(19)31939-9
doi: 10.1016/j.jcin.2019.09.015
pii:
doi:

Banques de données

JPRN
['UMIN000012140']

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2499-2511

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Eri Minamino-Muta (E)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Takao Kato (T)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. Electronic address: tkato75@kuhp.kyoto-u.ac.jp.

Takeshi Morimoto (T)

Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.

Tomohiko Taniguchi (T)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Chisato Izumi (C)

Division of Heart Failure, National Cerebral and Cardiovascular Center, Suita, Japan.

Kenji Nakatsuma (K)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Moriaki Inoko (M)

Cardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.

Shinichi Shirai (S)

Department of Cardiology, Kokura Memorial Hospital, Kokura, Japan.

Norio Kanamori (N)

Division of Cardiology, Shimada Municipal Hospital, Shimada, Japan.

Koichiro Murata (K)

Department of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.

Takeshi Kitai (T)

Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.

Yuichi Kawase (Y)

Department of Cardiovascular Medicine, Kurashiki Central Hospital, Kurashiki, Japan.

Makoto Miyake (M)

Department of Cardiology, Tenri Hospital, Tenri, Japan.

Hirokazu Mitsuoka (H)

Division of Cardiology, Nara Hospital, Kinki University Faculty of Medicine, Ikoma, Japan.

Yutaka Hirano (Y)

Department of Cardiology, Kinki University Hospital, Osakasayama, Japan.

Tomoki Sasa (T)

Kishiwada City Hospital, Kishiwada, Japan.

Kazuya Nagao (K)

Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan.

Tsukasa Inada (T)

Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan.

Ryusuke Nishikawa (R)

Department of Cardiology, Shizuoka General Hospital, Shizuoka, Japan.

Yasuyo Takeuchi (Y)

Department of Cardiology, Shizuoka General Hospital, Shizuoka, Japan.

Shintaro Matsuda (S)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Keiichiro Yamane (K)

Department of Cardiology, Nishikobe Medical Center, Kobe, Japan.

Kanae Su (K)

Department of Cardiology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.

Akihiro Komasa (A)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Katsuhisa Ishii (K)

Department of Cardiology, Kansai Electric Power Hospital, Osaka, Japan.

Yoshihiro Kato (Y)

Department of Cardiology, Saiseikai Noe Hospital, Osaka, Japan.

Kensuke Takabayashi (K)

Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan.

Shin Watanabe (S)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Naritatsu Saito (N)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Kenji Minatoya (K)

Department of Cardiovascular Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Takeshi Kimura (T)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH